Du Toit A. Outbreak of a Novel Coronavirus. Nat Rev Microbiol. 2020;18(3):123. doi: 10.1038/s41579-020-0332-0..
DOI: 10.1038/s41579-020-0332-0

Zhou P., Yang X., Wang X., Hu B., Zhang L., Zhang W. et al. A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat origin. Nature. 2020;579(7798):270–273. doi: 10.1038/s41586-020-2012-7..
DOI: 10.1038/s41586-020-2012-7

Li B., Yang J., Zhao F., Zhi L., Wang X., Liu L. et al. Prevalence and Impact of Cardiovascular Metabolic Diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531–538. doi: 10.1007/s00392-020-01626-9..
DOI: 10.1007/s00392-020-01626-9

Vaduganathan M., Vardeny O., Michel T., McMurray J.J. V., Pfeffer M.A., Solomon S.D. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with COVID-19. N Engl J Med. 2020;382(17):1653–1659. doi: 10.1056/NEJMsr2005760..
DOI: 10.1056/NEJMsr2005760

Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. et al. Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5..
DOI: 10.1016/S0140-6736(20)30183-5

Fang L., Karakiulakis G., Roth M. Are Patients with Hypertension and Diabetes Mellitus at Increased Risk for COVID-19 Infection? Lancet Respir Med. 2020;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8.
DOI: 10.1016/S2213-2600(20)30116-8

Esler M., Esler D. Can Angiotensin Receptor-Blocking Drugs Perhaps Be Harmful in the COVID-19 Pandemic? J Hypertens. 2020;38(5):781–782. doi: 10.1097/HJH.0000000000002450..
DOI: 10.1097/HJH.0000000000002450

De Simone G. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. European Society of Cardiology Council on Hypertension; 2020. Available at: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/positionstatement-of-the-esc-council-on-hypertension-on-aceinhibitors-and-ang.https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/positionstatement-of-the-esc-council-on-hypertension-on-aceinhibitors-and-ang

De Simone G. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. European Society of Cardiology Council on Hypertension; 2020. Available at: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/positionstatement-of-the-esc-council-on-hypertension-on-aceinhibitors-and-ang.https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/positionstatement-of-the-esc-council-on-hypertension-on-aceinhibitors-and-ang

Trifirò G., Crisafulli S., Andò G., Racagni G., Drago F. Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers Be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)? Drug Saf. 2020;43(6):507– 509. doi: 10.1007/s40264-020-00935-2..
DOI: 10.1007/s40264-020-00935-2

Kreutz R., Algharably E.A. E., Azizi M., Dobrowolski P., Guzik T., Januszewicz A. et al. Hypertension, the Renin-Angiotensin System, and the Risk of Lower Respiratory Tract Infections and Lung Injury: Implications for COVID-19. Cardiovasc Res. 2020;116(10):1688–1699. doi: 10.1093/cvr/cvaa097..
DOI: 10.1093/cvr/cvaa097

Unger T., Borghi C., Charchar F., Khan N.A., Poulter N.R., Prabhakaran D. et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. J Hypertens. 2020;38(6):982–1004. doi: 10.1097/HJH.0000000000002453..
DOI: 10.1097/HJH.0000000000002453

Bozkurt B., Kovacs R., Harrington B. Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. J Card Fail. 2020;26(5):370. doi: 10.1016/j.cardfail.2020.04.013..
DOI: 10.1016/j.cardfail.2020.04.013

Cohen J.B., Hanff T.C., Bress A.P., South A.M. Relationship between ACE2 and Other Components of the Renin-Angiotensin System. Curr Hypertens Rep. 2020;22(7):44. doi: 10.1007/s11906-020-01048-y..
DOI: 10.1007/s11906-020-01048-y

Hoffmann M., Kleine-Weber H., Schroeder S., Krüger N., Herrler T., Erichsen S. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271–280. doi: 10.1016/j.cell.2020.02.052..
DOI: 10.1016/j.cell.2020.02.052

Ferrario C.M., Jessup J., Chappell M.C., Averill D.B., Brosnihan K.B., Tallant E.A. et al. Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2. Circulation. 2005;111(20):2605–2610. doi: 10.1161/CIRCULATIONAHA.104.510461..
DOI: 10.1161/CIRCULATIONAHA.104.510461

Brojakowska A., Narula J., Shimony R., Bander J. Clinical Implications of SARS-CoV-2 Interaction with Renin Angiotensin System: JACC Review Topic of the Week. J Am Coll Cardiol. 2020;75(24):3085–3095. doi: 10.1016/j.jacc.2020.04.028..
DOI: 10.1016/j.jacc.2020.04.028

Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O. et al. Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation. Science. 2020;367(6483):1260–1263. doi: 10.1126/science.abb2507..
DOI: 10.1126/science.abb2507

Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi: 10.1056/NEJMoa2002032..
DOI: 10.1056/NEJMoa2002032

Al-Baadani A.M., Elzein F.E., Alhemyadi S.A., Khan O.A., Albenmousa A.H., Idrees M.M. Characteristics and Outcome of Viral Pneumonia Caused by Influenza and Middle East Respiratory Syndrome-Coronavirus Infections: A 4-Year Experience from a Tertiary Care Center. Ann Thorac Med. 2019;14(3):179–185. doi: 10.4103/atm.ATM_179_18..
DOI: 10.4103/atm.ATM_179_18

Wang Z., Chen Z., Zhang L., Wang X., Hao G., Zhang Z. et al. Status of Hypertension in China: Results from the China Hypertension Survey, 2012-2015. Circulation. 2018;137(22):2344–2356. doi: 10.1161/CIRCULATIONAHA.117.032380..
DOI: 10.1161/CIRCULATIONAHA.117.032380

Omar M.B. COVID-19 and the Angiotensin-Converting Enzyme (ACE2): Areas for Research. Heart Lung. 2020;49(4):351. doi: 10.1016/j.hrtlng.2020.04.012..
DOI: 10.1016/j.hrtlng.2020.04.012

Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S. et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–943. doi: 10.1001/jamainternmed.2020.0994..
DOI: 10.1001/jamainternmed.2020.0994

Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. et al. Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study. Lancet. 2020;395(10229):1054–1062. doi: 10.1016/S0140-6736(20)30566-3..
DOI: 10.1016/S0140-6736(20)30566-3

Wu J.T., Leung K., Bushman M., Kishore N., Niehus R., de Salazar P.M. et al. Estimating Clinical Severity of COVID-19 from the Transmission Dynamics in Wuhan, China. Nat Med. 2020;26(4):506–510. doi: 10.1038/s41591-020-0822-7..
DOI: 10.1038/s41591-020-0822-7

Fosbøl E.L., Butt J.H., Østergaard L., Andersson C., Selmer C., Kragholm K. et al. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality. JAMA. 2020;324(2):168–177. doi: 10.1001/jama.2020.11301..
DOI: 10.1001/jama.2020.11301

Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y. et al. Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study. Lancet. 2020;395(10223):507–513. doi: 10.1016/S0140-6736(20)30211-7..
DOI: 10.1016/S0140-6736(20)30211-7

Meng J., Xiao G., Zhang J., He X., Ou M., Bi J. et al. Renin–Angiotensin System Inhibitors Improve the Clinical Outcomes of COVID-19 Patients with Hypertension. Emerg Microbes Infect. 2020;9(1):757–760. doi: 10.1080/22221751.2020.1746200..
DOI: 10.1080/22221751.2020.1746200

Feng Y., Ling Y., Bai T., Xie Y., Huang J., Li J. et al. COVID-19 with Different Severity: A Multi-Center Study of Clinical Features. Am J Respir Crit Care Med. 2020;201(11):1380–1388. doi: 10.1164/rccm.202002-0445OC..
DOI: 10.1164/rccm.202002-0445OC

Li J., Wang X., Chen J., Zhang H., Deng A. Association of Renin–Angiotensin System Inhibitors with Severity or Risk of Death in Patients with Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. JAMA Cardiol. 2020;5(7):825–830. doi: 10.1001/jamacardio.2020.1624..
DOI: 10.1001/jamacardio.2020.1624

Yang G., Tan Z., Zhou L., Yang M., Peng L., Liu J. et al. Effects of ARBs and ACEIs on Virus Infection, Inflammatory Status and Clinical Outcomes in COVID-19 Patients with Hypertension: A Single Center Retrospective Study. Hypertension. 2020;76(1):51–58. doi: 10.1161/HYPERTENSIONAHA.120.15143..
DOI: 10.1161/HYPERTENSIONAHA.120.15143

Zhang P., Zhu L., Cai J., Lei F., Qin J.J., Xie J. et al. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality among Patients with Hypertension Hospitalized with COVID-19. Circ Res. 2020;26(12):1671–1681. doi: 10.1161/CIRCRESAHA.120.317134..
DOI: 10.1161/CIRCRESAHA.120.317134

Grover A., Oberoi M. A Systematic Review and Meta-Analysis to Evaluate the Clinical Outcomes in COVID-19 Patients on Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers. Eur Heart J Cardiovasc Pharmacother. 2020; 7(2):148–157. doi: 10.1093/ehjcvp/pvaa064..
DOI: 10.1093/ehjcvp/pvaa064

Guo T., Fan Y., Chen M., Wu X., Zhang L., He T. et al. Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811–818. doi: 10.1001/jamacardio.2020.1017..
DOI: 10.1001/jamacardio.2020.1017

Richardson S., Hirsch J.S., Narasimhan M., Crawford J.M., McGinn T., Davidson K.W. Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients Hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323(20):2052–2059. doi: 10.1001/jama.2020.6775..
DOI: 10.1001/jama.2020.6775

Palmeri V., Colamesta V., La Torre G. Evaluation of Methodological Quality of Studies. Senses Sci. 2016;3(3):235–241. doi: 10.14616/sands-2016-3-235241..
DOI: 10.14616/sands-2016-3-235241

Mancia G., Rea F., Ludergnani M., Apolone G., Corrao G. Renin-AngiotensinAldosterone System Blockers and the Risk of COVID-19. N Engl J Med. 2020;382(25):2431–2440. doi: 10.1056/NEJMoa2006923..
DOI: 10.1056/NEJMoa2006923

Reynolds H.R., Adhikari S., Pulgarin C., Troxel A.B., Iturrate E., Johnson S.B. et al. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of COVID-19. N Engl J Med. 2020;382(25):2441–2448. doi: 10.1056/NEJMoa2008975..
DOI: 10.1056/NEJMoa2008975

Reynolds H.R., Adhikari S., Pulgarin C., Troxel A.B., Iturrate E., Johnson S.B. et al. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of COVID-19. N Engl J Med. 2020;382(25):2441–2448. doi: 10.1056/NEJMoa2008975..
DOI: 10.1056/NEJMoa2008975

McEvoy J.W. Coronavirus (COVID-19) ACEi/ARB investigation (CORONACION). U.S. National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT04330300.https://clinicaltrials.gov/ct2/show/NCT04330300

McEvoy J.W. Coronavirus (COVID-19) ACEi/ARB investigation (CORONACION). U.S. National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT04330300.https://clinicaltrials.gov/ct2/show/NCT04330300

Hôpitaux de Paris. ACE inhibitors or ARBs discontinuation in context of SARS-CoV-2 pandemic (ACORES-2). U.S. National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT04329195.https://clinicaltrials.gov/ct2/show/NCT04329195

Hôpitaux de Paris. ACE inhibitors or ARBs discontinuation in context of SARS-CoV-2 pandemic (ACORES-2). U.S. National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT04329195.https://clinicaltrials.gov/ct2/show/NCT04329195

University of Minnesota. Losartan for Patients with COVID-19 Not Requiring Hospitalization. U.S. National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT04311177.https://clinicaltrials.gov/ct2/show/NCT04311177

University of Minnesota. Losartan for Patients with COVID-19 Not Requiring Hospitalization. U.S. National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT04311177.https://clinicaltrials.gov/ct2/show/NCT04311177

Furuhashi M., Moniwa N., Mita T., Fuseya T., Ishimura S., Ohno K. et al. Urinary Angiotensin-Converting Enzyme 2 in Hypertensive Patients May Be Increased by Olmesartan, an Angiotensin II Receptor Blocker. Am J Hypertens. 2015;28(1):15–21. doi: 10.1093/ajh/hpu086..
DOI: 10.1093/ajh/hpu086

De Abajo F.J., Rodríguez-Martín S., Lerma V., Mejía-Abril G., Aguilar M., García-Luque A. et al. Use of Renin–Angiotensin–Aldosterone System Inhibitors and Risk of COVID-19 Requiring Admission to Hospital: A CasePopulation Study. Lancet. 2020;395(10238):1705–1714. doi: 10.1016/S0140-6736(20)31030-8..
DOI: 10.1016/S0140-6736(20)31030-8

Zen Z. Hypertension in Patients Hospitalized with COVID-19 (HT-COVID19). U.S. National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT04318301.https://clinicaltrials.gov/ct2/show/NCT04318301

Zen Z. Hypertension in Patients Hospitalized with COVID-19 (HT-COVID19). U.S. National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT04318301.https://clinicaltrials.gov/ct2/show/NCT04318301

Di Castelnuovo A. ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19 (CODIV-ACE). U.S. National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT04318418.https://clinicaltrials.gov/ct2/show/NCT04318418

Di Castelnuovo A. ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19 (CODIV-ACE). U.S. National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT04318418.https://clinicaltrials.gov/ct2/show/NCT04318418

University of Minnesota. Losartan for Patients with COVID-19 Requiring Hospitalization. U.S. National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT04312009.https://clinicaltrials.gov/ct2/show/NCT04312009

University of Minnesota. Losartan for Patients with COVID-19 Requiring Hospitalization. U.S. National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT04312009.https://clinicaltrials.gov/ct2/show/NCT04312009

Li Y. Recombinant Human Angiotensinconverting Enzyme 2 (rhACE2) as a Treatment for Patients with COVID-19. U.S. National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT04287686.https://clinicaltrials.gov/ct2/show/NCT04287686

Li Y. Recombinant Human Angiotensinconverting Enzyme 2 (rhACE2) as a Treatment for Patients with COVID-19. U.S. National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT04287686.https://clinicaltrials.gov/ct2/show/NCT04287686

Ye R., Liu Z. ACE2 Exhibits Protective Effects against LPS-Induced Acute Lung Injury in Mice by Inhibiting the LPS-TLR4 Pathway. Exp Mol Pathol. 2020;113:104350. doi: 10.1016/j.yexmp.2019.104350..
DOI: 10.1016/j.yexmp.2019.104350

Kuster G.M., Pfister O., Burkard T., Zhou Q., Twerenbold R., Haaf P. et al. SARS-CoV2: Should Inhibitors of the Renin-Angiotensin System Be Withdrawn in Patients with COVID-19? Eur Heart J. 2020;41(19):1801– 1803. doi: 10.1093/eurheartj/ehaa235..
DOI: 10.1093/eurheartj/ehaa235

Liu Y., Yang Y., Zhang C., Huang F., Wang F., Yuan J. et al. Clinical and Biochemical Indexes from 2019-nCoV Infected Patients Linked to Viral Loads and Lung Injury. Sci China Life Sci. 2020;63(3):364–374. doi: 10.1007/s11427-020-1643-8..
DOI: 10.1007/s11427-020-1643-8

Dijkman R., Jebbink M.F., Deijs M., Milewska A., Pyrc K., Buelow E. et al. Replication-Dependent Downregulation of Cellular AngiotensinConverting Enzyme 2 Protein Expression by Human Coronavirus NL63. J Gen Virol. 2012;93(Pt 9):1924–1929. doi: 10.1099/vI.0.043919-0..
DOI: 10.1099/vI.0.043919-0

Dijkman R., Jebbink M.F., Deijs M., Milewska A., Pyrc K., Buelow E. et al. Replication-Dependent Downregulation of Cellular AngiotensinConverting Enzyme 2 Protein Expression by Human Coronavirus NL63. J Gen Virol. 2012;93(Pt 9):1924–1929. doi: 10.1099/vI.0.043919-0..
DOI: 10.1099/vI.0.043919-0

Gu H., Xie Z., Li T., Zhang S., Lai C., Zhu P. et al. Angiotensin-Converting Enzyme 2 Inhibits Lung Injury Induced by Respiratory Syncytial Virus. Sci Rep. 2016;6:19840. doi: 10.1038/srep19840..
DOI: 10.1038/srep19840

Gao C., Cai Y., Zhang K., Zhou L., Zhang Y., Zhang X. et al. Association of Hypertension and Antihypertensive Treatment with COVID-19 Mortality: A Retrospective Observational Study. Eur Heart J. 2020;41(22):2058–2066. doi: 10.1093/eurheartj/ehaa433..
DOI: 10.1093/eurheartj/ehaa433

Gurwitz D. Angiotensin Receptor Blockers as Tentative SARS-CoV-2 Therapeutics. Drug Dev Res. 2020;81(5):537–540. doi: 10.1002/ddr.21656..
DOI: 10.1002/ddr.21656

Shi S., Qin M., Shen B., Cai Y., Liu T., Yang F. et al. Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802–810. doi: 10.1001/jamacardio.2020.0950..
DOI: 10.1001/jamacardio.2020.0950

Halliday B.P., Wassall R., Lota A.S., Khalique Z., Gregson J., Newsome S. et al. Withdrawal of Pharmacological Treatment for Heart Failure in Patients with Recovered Dilated Cardiomyopathy (TRED-HF): An OpenLabel, Pilot, Randomised Trial. Lancet. 2019;393(10166):61–73. doi: 10.1016/S0140-6736(18)32484-X..
DOI: 10.1016/S0140-6736(18)32484-X

Di Somma S. Importance of Rapid and Effective Reduction of Blood Pressure in Treating Hypertension for the Prevention of Cardiovascular Diseases: A Lesson from the VALUE Study. High Blood Press Cardiovasc Prev. 2005;12(3):135–140. doi: 10.2165/00151642-200512030-00004..
DOI: 10.2165/00151642-200512030-00004

Lopes R.D., Macedo A.V. S., de Barros E. Silva P.G. M., Moll-Bernardes R.J., Dos Santos T.M. et al. Effect of Discontinuing vs Continuing AngiotensinConverting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted with COVID-19: A Randomized Clinical Trial. JAMA. 2021;325(3):254–264. doi: 10.1001/jama.2020.25864..
DOI: 10.1001/jama.2020.25864

Cohen J.B., Hanff T.C., William P., Sweitzer N., Rosado-Santander N.R., Medina C. et al. Continuation Versus Discontinuation of Renin-Angiotensin System Inhibitors in Patients Admitted to Hospital with COVID-19: A Prospective, Randomised, Open-Label Trial. Lancet Respir Med. 2021;9(3):275–284. doi: 10.1016/S2213-2600(20)30558-0..
DOI: 10.1016/S2213-2600(20)30558-0

Yusuf S., Joseph P., Rangarajan S., Islam S., Mente A., Hystad P. et al. Modifiable Risk Factors, Cardiovascular Disease, and Mortality in 155 722 Individuals from 21 High-Income, Middle-Income, and Low-Income Countries (PURE): A Prospective Cohort Study. Lancet. 2020;395(10226):795–808. doi: 10.1016/S0140-6736(19)32008-2..
DOI: 10.1016/S0140-6736(19)32008-2

Whelton P.K., Carey R.M., Aronow W.S., Casey D.E. Jr., Collins K.J., Dennison Himmelfarb С. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127–e248. doi: 10.1016/j.jacc.2017.11.006..
DOI: 10.1016/j.jacc.2017.11.006

Williams B., Mancia G., Spiering W., Agabiti Rosei E., Azizi M., Burnier M. et al. 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension. Eur Heart J. 2018;39(33):3021–3104. doi: 10.1093/eurheartj/ehy339..
DOI: 10.1093/eurheartj/ehy339

Whelton S.P., McEvoy J. W., Shaw L., Psaty B.M., Lima J.A. C., Budoff M. et al. Association of Normal Systolic Blood Pressure Level with Cardiovascular Disease in the Absence of Risk Factors. JAMA Cardiol. 2020;5(9):1011– 1018. doi: 10.1001/jamacardio.2020.1731..
DOI: 10.1001/jamacardio.2020.1731

Chalmers J., Arima H., Woodward M., Mancia G., Poulter N., Hirakawa Y. et al. Effects of Combination of Perindopril, Indapamide, and Calcium Channel Blockers in Patients with Type 2 Diabetes Mellitus: Results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) Trial. Hypertension. 2014;63(2):259–264. doi: 10.1161/HYPERTENSIONAHA.113.02252..
DOI: 10.1161/HYPERTENSIONAHA.113.02252

Кобалава Ж.Д., Троицкая Е.А., Толкачева В.В. Комбинированная терапия артериальной гипертонии с использованием трехкомпонентной фиксированной комбинации амлодипина, индапамида и периндоприла аргинина в клинической практике: организация и основные результаты программы ДОКАЗАТЕЛЬСТВО. Кардиология. 2018;58(9):21–30. doi: 10.18087/cardio.2018.9.10170..
DOI: 10.18087/cardio.2018.9.10170

Кобалава Ж.Д., Толкачева В.В., Троицкая Е.А., Колесникова И.А., Маркова М.А. Фиксированная тройная комбинация амлодипин/индапамид/ периндоприла аргинин–рациональный и безопасный выбор для контроля артериального давления в реальной клинической практике (результаты наблюдательной программы ДОКАЗАТЕЛЬСТВО). Российский кардиологический журнал. 2020;25(6):3805. doi: 10.15829/1560-4071-2020-3805..
DOI: 10.15829/1560-4071-2020-3805